Multicenter, randomized, parallel-group, double-blind, placebo-controlled phase 3 study of the efficacy and safety of quetiapine fumarate and lithium as monotherapy for up to 104 weeks maintenance treatment of bipolar I disorder in adult patients

Trial Profile

Multicenter, randomized, parallel-group, double-blind, placebo-controlled phase 3 study of the efficacy and safety of quetiapine fumarate and lithium as monotherapy for up to 104 weeks maintenance treatment of bipolar I disorder in adult patients

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Quetiapine (Primary) ; Lithium
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SPaRCLe
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)
    • 12 Jul 2011 Planned end date 22 Jun 2008 added as reported by EudraCT.
    • 01 Apr 2008 Primary endpoint 'Time to disease recurrence' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top